FDA approves Orzeyful as first treatment to address the full range of narcolepsy type 1 symptoms
- nuaxia
- Aug 7
- 2 min read
The orexin receptor agonist provides adults with a treatment that targets the underlying loss of orexin signalling rather than managing individual symptoms separately.
The US Food and Drug Administration (FDA) has approved Orzeyful (oveporexton) for the treatment of adults with narcolepsy type 1, making it the first medicine approved to address the condition as a complete disorder by restoring orexin signalling.
The approval introduces a new therapeutic approach for patients experiencing excessive daytime sleepiness, cataplexy and other symptoms, although commercial launch must await scheduling by the US Drug Enforcement Administration (DEA).
Field | Content |
Alert Type | Drug Approval |
Drug Name | Orzeyful (oveporexton) |
Indication | Treatment of narcolepsy type 1 in adults. |
Therapy Area(s) | Neurology; Sleep Medicine |
Geography | United States (FDA) |
What Happened | On 5 August 2026, the FDA approved Orzeyful (oveporexton) for adults with narcolepsy type 1. The twice-daily oral treatment is the first approved therapy designed to address the disorder as a whole and the first to directly activate orexin receptors, targeting the loss of orexin signalling underlying the condition. The FDA has recommended scheduling under the Controlled Substances Act, and Orzeyful cannot be marketed until the DEA issues its final scheduling decision. |
Why It Matters | Current narcolepsy treatments generally manage individual manifestations such as excessive daytime sleepiness or cataplexy. Orzeyful introduces a different approach by targeting the underlying orexin deficiency and demonstrated improvements across multiple symptoms, including wakefulness, daytime sleepiness, cataplexy, sleep paralysis, hallucinations and disrupted night-time sleep. |
Supporting Context | Narcolepsy type 1 is caused by the loss of orexin-producing neurons, disrupting regulation of wakefulness, sleep and muscle tone. Approval was supported by two randomised, double-blind, placebo-controlled 12-week trials involving 273 adults, with common adverse reactions including insomnia, increased urinary frequency, urinary urgency and increased saliva production. |
Key Takeaway | Orzeyful is the first FDA-approved treatment to target the underlying orexin deficiency while addressing the broad range of symptoms experienced by adults with narcolepsy type 1. |
What to Watch | The DEA scheduling decision will determine when Orzeyful can enter the US market, after which commercial availability, reimbursement and clinical uptake will determine patient access. |
Primary Source | |
Relevant Date | 5 August 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comments